Based on Phase III studies, ICIs are now included in major urology guidelines for use as second-line treatment in platinum-relapsed patients, and as first-line treatment in platinum-ineligible metastatic bladder cancer patients on the condition of high PD-L1 tumor cell expression [2]. This evidence concerns the gene CD274 and neoplasm.